DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jb Reed - 1 It's - 1 Erin Fox - 1 they've - 1 David Margraf - 1 Margraf - 1 drugmakers - 1 Ozlem Ergun - 1
Top related locs:
U.S Commerce City , Colorado
Top related orgs:
Shire Plc - 1 Jb - 1 Bloomberg - 1 Getty - 1 and Drug Administration - 1 CNBC - 1 University of Utah - 1 American Society of Health - 1

Search resuls for: "Novartis's"


5 mentions found


☆ The ADHD drug market is already stretched thin. Now it's facing a back-to-school supply strain
  + stars: | 2023-08-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +8 min
Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc. Adderall and alternative ADHD medications apart from other drugs are Schedule 2 controlled substances. Production limitationsEnding the shortages of Adderall and other ADHD medications is no easy task. That means increasing the production of one drug could potentially require reducing production — and potentially impacting supply — of another drug, according to Ergun. That includes Aytu BioPharma, which makes an ADHD drug that used to be in shortage.
Persons: Jb Reed, It's, Erin Fox, they've, David Margraf, Margraf, drugmakers, Ozlem Ergun, Ergun, Novartis's, Michael Ganio, ASHP's Ganio, RJ Sangosti, Josh Disbrow, Fox Organizations: Shire Plc, Jb, Bloomberg, Getty, and Drug Administration, CNBC, University of Utah, American Society of Health, System Pharmacists, Centers for Disease Control, University of Minnesota's, Infectious Disease, Northeastern University, Teva Pharmaceuticals, Amneal Pharmaceuticals, Sandoz, Purdue Pharma, Rhodes Pharmaceuticals, Drug, Fox, Pharmacists, Drug Enforcement Administration, MediaNews, Denver, FDA, DEA Locations: U.S, Commerce City , Colorado
☆ Novartis buoyed by trial success in early-stage breast cancer
  + stars: | 2023-03-27 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
The Swiss firm's shares jumped 5.8% on Monday to a four-week high by 0734 GMT, after it said a panel of independent supervisors recommended stopping the trial early because an interim analysis had shown a clear benefit. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other body parts, where it has taken market share from Pfizer's (PFE.N) Ibrance. Rival drug Verzenio by Eli Lilly (LLY.N) has approval in the early setting for women at high risk of recurrence after surgery. Kisqali, which saw sales gain 31% to $1.2 billion last year, is one of two new drugs with a particularly important role for the group's future sales growth. Detailed trial results will be presented at a medical conference, Novartis said, without identifying the meeting or its timing.
☆ Novartis initiates new trading line for share buybacks
  + stars: | 2023-03-13 | by ( Ludwig Burger | ) www.reuters.com   time to read: +1 min
March 13 (Reuters) - Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchases even as its ongoing $15 billion buyback programme is close to completion. At last week's annual shareholder meeting, the company won investor authorization for up to 10 billion francs in buybacks, which comes on top of 6.5 billion francs in prior authorizations. A company spokesperson told Reuters on Monday that the "majority" of its ongoing $15 billion buyback programme was already completed, adding that any repurchases would be decided by the board of directors. Novartis laid out plans for the $15 billion programme in late 2021, after receiving $20.7 billion for the sale of its nearly one-third voting stake in Roche (ROG.S) back to its cross-town rival. ($1 = 0.9118 Swiss francs)Reporting by Ludwig Burger in Frankfurt and John Revill in Zurich Editing by Paul Carrel and Christina FincherOur Standards: The Thomson Reuters Trust Principles.
☆ Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
  + stars: | 2022-12-29 | by ( Jonathan Stempel | ) www.reuters.com   time to read: +1 min
NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S) said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug. The class-action litigation stemmed from a 2011 licensing agreement between Novartis and Endo International Plc's (ENDPQ.PK) Par Pharmaceutical unit. Novartis's annual U.S. sales of brand-name Exforge exceeded $400 million before generic versions were sold, court papers show. The case is In re Novartis and Par Antitrust Litigation, U.S. District Court, Southern District of New York, No. Reporting by Jonathan Stempel in New York; Editing by Muralikumar Anantharaman and Bradley PerrettOur Standards: The Thomson Reuters Trust Principles.
☆ Novartis debuted its first integrated sustainability and finance report this year — more companies are likely to follow suit
  + stars: | 2022-07-06 | by ( Julia Hood | ) www.businessinsider.com   time to read: +5 min
A coalition of sustainability organizations has recommended integrated reporting to improve the quality of information. Global organizations for decades have wrangled with not just what to report on sustainability goals, but how to report. To learn more about the Novartis Access Principles, Insider turned to the company's integrated report. On May 25, 2022, the International Financial Reporting Standards Foundation (IFRS), the chairs of the International Accounting Standards Board (IASB), and the International Sustainability Standards Board (ISSB), announced they would be incorporating the IIRC's current framework. Novartis tapped the Integrated Reporting Framework in developing the report, as well as SASB Standards provided by the Value Reporting Foundation.
0 next >>
Total: 5